BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK ...
New clinical trial data show KRAS-blocking drugs may significantly improve survival for the disease. “I think this is truly ...
Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research findings in poster sessions at the American Association for Cancer Research ...
MedPage Today on MSN
Next-Generation KRAS G12C Inhibitor Shows 'Robust' Efficacy in Advanced Lung Cancer
Responses observed in patients with and without previous exposure to other KRAS G12C inhib ...
A late-stage clinical trial shows daraxonrasib, an oral RAS inhibitor, nearly doubles median survival for patients with ...
Pancreatic cancer pill vaccine shows promising trial results, nearly doubling survival and prompting phase 2 studies, per AACR reports.
Morning Overview on MSN
MSK study shows mutated cells reshape nearby tissue early, helping tumors take hold
A single genetic mutation in a lung cell can start rewriting the rules for the tissue around it almost immediately, ...
The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in ...
A company that is changing the outlook on pancreatic cancer has more promising data for treatments near-term and for a ...
Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current ...
Daraxonrasib, a pancreatic cancer drug from Revolution Medicines, is showing unprecedented success. For patients like Leanna ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results